Primo Biotechnology harnesses advanced molecular imaging and radiopharmaceutical science to provide precise clinical information via targeted radiopharmaceuticals. Primo Biotechnology aims to form a patient-centric healthcare model and establish doctor-patient relationships founded on trust towards conveying hope and happiness to all patients.
Future in Precision
Why Primo?
Primo Biotechnology embodies disruptive innovation that advances clinical procedures for cancer management with molecular image-guided and targeted diagnosis and therapy.
We are determined to lead in precision radiopharmaceutical approaches for the diagnosis and treatment of cancer.
Our breakthrough technology performs molecular-level targeted oncologic radiotherapy based on non-invasive PET imaging with the same molecule.
Why Primo Exceeds
The Primo team comprises professionals who own several patents in novel radiopharmaceuticals and new manufacturing processes, and are experienced in applications of TFDA/CDE in clinical investigations using new drugs. We are also highly specialized in radiopharmaceutical development.